Domov › Nemalicelični pljučni rak › Arizona
Klinične študije za Nemalicelični pljučni rak v Arizona
67 študij za Nemalicelični pljučni rak išče udeležence na lokacijah v Arizona.
Mesta v Arizona
- Phoenix20 študij
- Tucson17 študij
- Scottsdale15 študij
- Gilbert13 študij
- Goodyear8 študij
- Chandler5 študij
- Bullhead City4 študij
- Glendale3 študij
Uradno besedilo študije (angleško)
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- Ironwood Cancer and Research Center /ID# 276370, Chandler
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 5. okt. 2026 · NCT06568939Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Banner Boswell Medical Center, Sun City
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 5. okt. 2026 · NCT04267848Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
- Banner MD Anderson Cancer Center, Gilbert
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 5. okt. 2026 · NCT06784193A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- Banner MD Anderson Cancer Center ( Site 0181), Gilbert
- The University of Arizona Cancer Center - North Campus ( Site 0163), Tucson
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT06623422Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
- HonorHealth Research Institute, Scottsdale
Vključevanje udeležencevFaza 1/2
Starost 18 in več · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT07751042A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
- Research Site, Phoenix
Vključevanje udeležencevFaza 1/2
Starost 18 in več · Vsi spoli · Posodobljeno 1. okt. 2026 · NCT06996782Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #67, Phoenix
- Exelixis Clinical Site #1, Tucson
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 1. okt. 2026 · NCT05176483A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
- Mohtaseb Cancer Center & Blood Disorders, Bullhead City
- Palo Verde Hematology Oncology, Glendale
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 30. sep. 2026 · NCT07361510Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
- Palo Verde Hematology Oncology, Glendale
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 30. sep. 2026 · NCT06765109A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
- Research Site, Gilbert
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 29. sep. 2026 · NCT05877599Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
- Mayo Clinic in Arizona - Phoenix ( Site 0147), Phoenix
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT06170788Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
- Banner Health, Gilbert
- Mayo Clinic Hospital, Phoenix
Vključevanje udeležencevOpazovalna študija
Starost 18 in več · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT04981119Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Pioneer Research Center, Bullhead City
- Ironwood Cancer & Research Centers, Chandler
- Ironwood Cancer & Research Centers, Gilbert
- in še 6
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT07222566A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- City of Hope Phoenix, Goodyear
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT06667076A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Cancer Treatment Centers of America, Phoenix, Goodyear
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT07154290Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
- City of Hope, Phoenix, Phoenix
- The University of Arizona Cancer Center - North Campus, Tucson
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 24. sep. 2026 · NCT06890598Pan-tumor MRD Study
- Mohtaseb Cancer Center and Blood Disorders, Bullhead City
- Cancer & Blood Specialists of Arizona, Casa Grande
Vključevanje udeležencevOpazovalna študija
Starost 18 in več · Vsi spoli · Posodobljeno 24. sep. 2026 · NCT06605404Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
- Research Site, Tucson
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 23. sep. 2026 · NCT06357533A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
- Southern Arizona VA Health Care System, Tucson
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 23. sep. 2026 · NCT06561386Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
- Banner MD Anderson Cancer Center, Gilbert
- Arizona Cancer Center at UMC North/University Medical Center, Tucson
Vključevanje udeležencevFaza 1/2
Starost 18–99 · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT06814496A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
- Research Site, Tucson
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 18. sep. 2026 · NCT06692738A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors
- HonorHealth Research Institute, Scottsdale
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 18. sep. 2026 · NCT07705334Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
- Clinical Study Site, Chandler
- Clinical Study Site, Phoenix
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 18. sep. 2026 · NCT06767514Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- Banner Health- MD Anderson Cancer Center, Gilbert
Vključevanje udeležencevFaza 1/2
Starost 18 in več · Vsi spoli · Posodobljeno 16. sep. 2026 · NCT05786924Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
- Local Institution - 007-556-A, Goodyear
- USOR - Arizona Oncology - Prescott Valley, Prescott Valley
- Local Institution - 007-568-A, Safford
- in še 5
Vključevanje udeležencevFaza 2/3
Starost 18 in več · Vsi spoli · Posodobljeno 16. sep. 2026 · NCT04613596ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- Ironwood Cancer & Research Centers, Chandler
Vključevanje udeležencevOpazovalna študija
Starost 18 in več · Vsi spoli · Posodobljeno 14. sep. 2026 · NCT05059444A Study of KK2269 in Adult Participants With Solid Tumors
- Mayo Clinic Arizona, Scottsdale
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 10. sep. 2026 · NCT06266299A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Banner MD Anderson Cancer Center, Gilbert
- Banner University Medical Center Phoenix, Phoenix
- The University of Arizona Cancer Center - North Campus, Tucson
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 8. sep. 2026 · NCT06119581A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- City of Hope - Phoenix, Goodyear
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 8. sep. 2026 · NCT06793215A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
- HonorHealth, Scottsdale
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 4. sep. 2026 · NCT06400472A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
- HonorHealth Research Institute, Scottsdale
- Mayo Scottsdale, Scottsdale
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 4. sep. 2026 · NCT07361562Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
- Research Site, Chandler
- Research Site, Gilbert
- Research Site, Goodyear
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 4. sep. 2026 · NCT07291037Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
- Mayo Clinic, Phoenix
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 2. sep. 2026 · NCT05245500A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
- Mayo Clinic Arizona, Phoenix
Vključevanje udeležencevFaza 1/2
Starost 18 in več · Vsi spoli · Posodobljeno 2. sep. 2026 · NCT07070232A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
- Mayo Clinic Arizona, Phoenix
Vključevanje udeležencevFaza 1/2
Starost 18 in več · Vsi spoli · Posodobljeno 26. avg. 2026 · NCT06892548A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors
- HonorHealth Research Institute, Scottsdale
Vključevanje udeležencevFaza 1/2
Starost 18–75 · Vsi spoli · Posodobljeno 19. avg. 2026 · NCT07636785Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
- Mayo Clinic Hospital in Arizona, Phoenix
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 17. avg. 2026 · NCT06500481A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
- Mayo Clinic Hospital - Arizona, Phoenix
Vključevanje udeležencevFaza 1/2
Starost 18 in več · Vsi spoli · Posodobljeno 5. avg. 2026 · NCT06706076Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- USOR HonorHealth, Phoenix
- USOR Arizona Oncology Associates, Tucson
Vključevanje udeležencevFaza 1/2
Starost 18 in več · Vsi spoli · Posodobljeno 4. avg. 2026 · NCT05579366AOH1996 for the Treatment of Refractory Solid Tumors
- Honor Health Research and Innovation Institute, Scottsdale
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 28. jul. 2026 · NCT05227326Vir: ClinicalTrials.gov, podatki pridobljeni 6. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.